← Back to patent-cliff list
Sitagliptin/Ertugliflozin
Tier C — Watch / tradeSitagliptin/Ertugliflozin
Pfizer Inc.
Originator
2017
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：DPP4, SGLT2
Brand：Steglujan
Indications (approved)：Type 2 diabetes
Regional status
US
Approved
2017-12-19
EU
Approved
2018-03-23
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Sitagliptin/Ertugliflozin?
Approved indications include: Type 2 diabetes.
When does the Sitagliptin/Ertugliflozin patent expire?
No public expiry year is available for Sitagliptin/Ertugliflozin yet; this page updates once verified.
How do I get a quote for Sitagliptin/Ertugliflozin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29